Free tool
FAERS Monitor: Viibryd
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022567 or its brand name (Viibryd, Vilazodone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
9,233
Serious
3,618
39% of reports
Hospitalization
1,023
Death reported
188
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,096
- nausea786
- diarrhoea783
- anxiety635
- insomnia620
- drug ineffective566
- headache544
- depression492
- dizziness485
- fatigue463
- suicidal ideation417
- feeling abnormal402
- weight increased299
- paraesthesia296
- vomiting277
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2011 | 460 |
| 2012 | 1,132 |
| 2013 | 738 |
| 2014 | 524 |
| 2015 | 444 |
| 2016 | 880 |
| 2017 | 736 |
| 2018 | 562 |
| 2019 | 743 |
| 2020 | 829 |
| 2021 | 562 |
| 2022 | 484 |
| 2023 | 380 |
| 2024 | 296 |
| 2025 | 279 |
| 2026 | 183 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,926 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| suicidal ideationSignal | 417 | 10.4 | 9.5 | 3,541 |
| insomniaSignal | 620 | 5.3 | 4.9 | 2,189 |
| anxietySignal | 635 | 5.1 | 4.7 | 2,108 |
| depressionSignal | 492 | 4.9 | 4.5 | 1,553 |
| paraesthesiaSignal | 296 | 4.3 | 3.8 | 748 |
| feeling abnormalSignal | 402 | 3.8 | 3.5 | 845 |
| weight increasedSignal | 299 | 3.0 | 2.7 | 412 |
| off label useSignal | 1,096 | 2.9 | 2.7 | 1,373 |
| diarrhoeaSignal | 783 | 2.8 | 2.6 | 907 |
| nauseaSignal | 786 | 2.3 | 2.1 | 574 |
| dizzinessSignal | 485 | 2.2 | 2.0 | 330 |
| headache | 544 | 2.0 | 1.8 | 270 |
| fatigue | 463 | 1.4 | 1.2 | 44 |
| vomiting | 277 | 1.3 | 1.2 | 24 |
| drug ineffective | 566 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.